Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan’s 1st Acetaminophen IV Injection Now Available
November 26, 2013
- Chugai’s Avastin Approved for Ovarian Cancer Treatment
November 25, 2013
- AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
- Preminent Generics of 30-Plus Firms Likely to Carry “Losarhyd” Brand; Unified Trade Names Logged for 4 More Combination Generics
November 25, 2013
- Kyowa Kirin Launches New PIII Trial for Istradefylline
November 25, 2013
- ASKA Pharmaceutical Plans to Launch Generic Version of Takeda’s Leuplin, Aims for 20% Market Share
November 25, 2013
- Once-Monthly Injectable Abilify Maintena Approved in Europe: Otsuka
November 25, 2013
- Domestic Ethical Drug Market Estimated to Reach 9,617.7 Billion Yen in 2020: Fuji Keizai
November 22, 2013
- Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
- Mid-sized Foreign Drug Makers Eying Full-scale Entry into Japanese Market Encouraged by Favorable Changes in Market Environment; Marketing Systems May Be Key to Success
November 22, 2013
- Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
- Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
- Novartis’ Compliance Advisory Board Holds 1st Meeting amid Diovan Fuss
November 21, 2013
- JT’s Anti-HIV Agent Elvitegravir Wins European Regulatory Approval
November 21, 2013
- Bristol-Myers Italy Head Piras Sworn in as Japan President
November 21, 2013
- Shionogi Licenses 2 Oxycodone Products with Abuse-Deterrent Measures from Mundipharma
November 21, 2013
- US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
- Nichi-Iko to Collaborate with Hanoi Pharmaceutical of Vietnam
November 20, 2013
- Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
- CMIC Chairman Sorry for Alleged Clinical Data Tampering; Probe Report Due out Late November
November 18, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…